Edition:
United Kingdom

PeptiDream Inc (4587.T)

4587.T on Tokyo Stock Exchange

3,530JPY
22 Nov 2017
Change (% chg)

¥-150 (-4.08%)
Prev Close
¥3,680
Open
¥3,715
Day's High
¥3,715
Day's Low
¥3,525
Volume
1,516,000
Avg. Vol
1,009,773
52-wk High
¥3,915
52-wk Low
¥2,450

Chart for

About

PeptiDream Inc. is principally engaged in the research and development of new pharmaceutical candidates. The Company operates its business jointly with domestic and overseas pharmaceutical companies, through the application of Peptide Discovery Platform System (PDPS), which is its own drug discovery platform system. The Company... (more)

Overall

Beta: 0.71
Market Cap(Mil.): ¥420,400.41
Shares Outstanding(Mil.): 120.11
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.23 16.44
EPS (TTM): -- -- --
ROI: -- 2.53 10.62
ROE: -- 3.17 14.20

BRIEF-Peptidream announces discovery collaboration agreement with Bayer

* Peptidream announces discovery collaboration agreement with bayer

20 Nov 2017

BRIEF-PeptiDream announces discovery collaboration agreement with Bayer AG

* Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG

16 Nov 2017

BRIEF- PeptiDream announces change of chairman and president

* Says it appoints current president Kiichi Kubota as chairman of the board of the company

22 Aug 2017

REFILE-TABLE-Peptidream-2016/17 parent results

(Adds company forecast) Aug 9 (Reuters)- Peptidream Inc. PARENT-ONLY FINANCIAL HIGHLIGHTS (in billions of yen unless specified) Year ended Year ended Year to NEXT Jun 30, 2017 Jun 30, 2016 Jun 30, 2018 YEAR LATEST YEAR-AGO COMPANY COMPANY RESULTS RESULTS FORECAST H1 FORECAST Sales 4.90 4.33   more than 7.00 (+13.1 pc

09 Aug 2017

BRIEF-PeptiDream to set up Osaka-based special peptide drugs JV

* Says it plans to set up Osaka-based joint venture with Shionogi & Co., Ltd and Sekisui Chemical Co., Ltd. , on Sept. 1

07 Aug 2017

BRIEF- Sosei Group subsidiary Heptares enters strategic collaboration with PeptiDream

* Says its unit Heptares Therapeutics and PeptiDream Inc , a public Tokyo-based biopharmaceutical company, have entered into a strategic collaboration to discover, develop and commercialise novel therapeutics targeting an undisclosed G protein-coupled receptor (GPCR) with an important role in inflammatory diseases

29 Jun 2017

BRIEF- PeptiDream announces licensing of peptide discovery platform system (PDPS) technology to Shionogi

* Says it has entered into a technology license agreement with Osaka-based Shionogi & Co Ltd, to nonexclusively license PeptiDream’s proprietary Peptide discovery platform system (PDPS) technology

12 Jun 2017

BRIEF-PeptiDream announces completion of technology transfer of Peptide Discovery Platform System to Lilly

* Says it completes the technology transfer of the Peptide Discovery Platform System (PDPS) to US-based Eli Lilly and Company

07 Jun 2017

BRIEF-PeptiDream announces completion of technology transfer of Peptide Discovery Platform System to Genentech

* Says it completes the technology transfer of the Peptide Discovery Platform System (PDPS) to Genentech

31 May 2017

Earnings vs. Estimates